Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259605 | 0.85 | MAPT (1.00) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL14104057 | 0.85 | MAPT (0.77) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL29397956 | 0.85 | MAPT (1.00) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL9070025 | 0.83 | L3MBTL1 (1.00) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL22287878 | 0.81 | MAPT (0.76) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL17859660 | 0.80 | KDM4E (0.72) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL25311259 | 0.79 | MAPT (0.67) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL14104058 | 0.77 | KMT2A (0.70) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL13137734 | 0.76 | MEN1 (0.62) | MAPTL3MBTL1HPGDPOLBKDM4E | |
| SCHEMBL14104417 | 0.76 | HPGD (0.79) | MAPTL3MBTL1HPGDPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MAPT 2121/4885L3MBTL1 116/4885HPGD 4849/4885 |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MAPT 2121/4885L3MBTL1 116/4885HPGD 4849/4885 |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | MAPT 1267/4885L3MBTL1 181/4885HPGD 4822/4885 |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | MAPT 1907/4885L3MBTL1 115/4885HPGD 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.